Adial Pharmaceuticals regains Nasdaq compliance with stockholders' equity requirement after $3.6M offering

ADIAL PHARMACEUTICALS, INC.

Nasdaq confirmed compliance with Listing Rule 5550(b)(1) as of July 14, 2025.
Deficiency arose from $2.13M equity as of Mar 31, 2025, below $2.5M minimum.
June 2025 best-efforts offering raised ~$3.6M gross via shares and warrants.
Nasdaq will monitor ongoing compliance; next periodic report may trigger re-evaluation.

item 8.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.